How semaglutide is dosed in approved indications

Dosing schedules, in plain terms

Semaglutide is started at a low dose and stepped up every four weeks. The slow escalation is designed to keep nausea manageable while building toward a therapeutically effective dose.

For chronic weight management, the documented subcutaneous schedule ends at 2.4 mg once weekly — the dose studied in STEP 1, STEP 5, SELECT, and STEP-HFpEF. For type 2 diabetes, the documented subcutaneous range runs from 0.5 mg to 2.0 mg weekly. The oral tablet, used for diabetes and (at higher doses) weight management, must be taken on an empty stomach with only a small amount of plain water — absorption depends on it.

Every schedule on this page is drawn from the FDA prescribing information or pivotal trial protocols. These are not instructions for any individual — dosing decisions belong with a licensed prescriber.

Two formulations, two routes

Semaglutide is available in two FDA-approved formulations:

1. Subcutaneous injection, administered once weekly via a pre-filled pen. Used for type 2 diabetes, chronic weight management, cardiovascular risk reduction, and (pending the kidney indication) chronic kidney disease in type 2 diabetes.
2. Oral tablet, administered once daily and co-formulated with the absorption enhancer SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate), which enables intestinal absorption of the peptide. Used for type 2 diabetes; a high-dose oral formulation was approved for weight management in late 2025 ^[20].

The pharmacokinetic properties — subcutaneous bioavailability 89%, oral bioavailability 0.4–1%, half-life roughly 165–184 hours, albumin binding >99% — are the same molecule in both cases ^[17]. The difference is route, frequency, and labeling.

What follows is a summary of the dosing schedules as described in the FDA prescribing information and the pivotal trials. This is editorial commentary, not a prescription. Actual dosing decisions are made by a licensed clinician based on the individual patient.

Subcutaneous once-weekly: type 2 diabetes

For type 2 diabetes, the FDA-approved subcutaneous titration is built around four maintenance doses: 0.25 mg, 0.5 mg, 1.0 mg, and 2.0 mg.

The standard titration schedule is:

• Weeks 1–4: 0.25 mg once weekly. This is an initiation dose only, designed to mitigate gastrointestinal side effects. It is not therapeutic.
• Weeks 5–8: 0.5 mg once weekly. The first therapeutic maintenance dose.
• Optional escalation to 1.0 mg once weekly after at least 4 weeks at 0.5 mg, if additional glycemic control is needed.
• Optional escalation to 2.0 mg once weekly after at least 4 weeks at 1.0 mg.

The SUSTAIN program studied the 0.5 mg and 1.0 mg doses in the foundational trials ^[1][6][13]; the 2.0 mg dose was added later based on the SUSTAIN FORTE trial. The injection is administered into the abdomen, thigh, or upper arm and can be given at any time of day, with or without food.

Subcutaneous once-weekly: chronic weight management

For chronic weight management in adults with BMI >=30, or BMI >=27 with a weight-related comorbidity, the titration extends one step further:

• Weeks 1–4: 0.25 mg once weekly
• Weeks 5–8: 0.5 mg once weekly
• Weeks 9–12: 1.0 mg once weekly
• Weeks 13–16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance)

The 2.4 mg weekly dose is the one studied in the STEP program (STEP 1, STEP 5, STEP 8, STEP TEENS, STEP-HFpEF) and in the SELECT trial ^{[2][3][8][9][10]}. The full 16-week titration is intended to allow GI tolerability to develop before the maintenance dose is reached; the prescribing information allows extended titration if side effects are limiting.

For adolescents aged 12 and older with obesity, the STEP TEENS trial used the same 2.4 mg maintenance dose after titration ^[9]. The pediatric indication was added in December 2022.

Oral once-daily: type 2 diabetes

Oral semaglutide is available in 3 mg, 7 mg, and 14 mg tablets for type 2 diabetes. The titration is:

• Weeks 1–4: 3 mg once daily (initiation; not therapeutic)
• Weeks 5 onward: 7 mg once daily (maintenance)
• Optional escalation to 14 mg once daily after at least 30 days at 7 mg, if additional glycemic control is needed.

Because oral bioavailability depends critically on the SNAC absorption enhancer, dosing is highly sensitive to administration conditions. The prescribing information directs that the tablet be taken on an empty stomach with no more than 120 mL (4 ounces) of plain water, at least 30 minutes before the first food, beverage, or other oral medication of the day. Co-administered food or fluid dramatically reduces absorption ^[5].

The PIONEER 6 cardiovascular safety trial used the 14 mg daily dose ^[5]. PIONEER PLUS investigated high-dose oral semaglutide (25 mg and 50 mg daily), which produced larger HbA1c and weight reductions than 14 mg; the 25 mg oral dose was approved for weight management in late 2025 ^[20].

Cardiovascular, kidney, and MASH indications

The non-diabetes cardiovascular indication (approved March 2024 based on SELECT) uses the same 2.4 mg weekly subcutaneous maintenance dose as the weight-management indication ^[3]. The titration schedule is identical.

The kidney/CV-death indication in type 2 diabetes with chronic kidney disease (approved 2025 based on FLOW) uses the 1.0 mg weekly subcutaneous dose ^[4]. The FLOW trial titration went 0.25 mg → 0.5 mg → 1.0 mg over 16 weeks.

The ESSENCE MASH trial, which underlies the pending regulatory submission, used the 2.4 mg weekly subcutaneous dose ^[11]. If approved, the MASH labeling is expected to follow the same titration as the weight-management indication.

Pharmacokinetic context

A few PK facts contextualize the dosing schedule ^[17]:

• Half-life: approximately 165–184 hours (roughly one week). This is what makes once-weekly subcutaneous dosing feasible.
• Time to peak (subcutaneous): 1–3 days after injection.
• Steady state: reached after approximately 4–5 weeks of weekly administration — which is one reason titration steps are at least 4 weeks long.
• Albumin binding: >99%, which protects the molecule from renal clearance and contributes to the long half-life.
• Metabolism: proteolytic backbone cleavage and beta-oxidation of the fatty-acid side chain. Not CYP-dependent, so drug-drug interactions of the conventional small-molecule kind are minimal.
• Excretion: primarily renal and fecal; only about 3% excreted unchanged in urine.

The long half-life also has a practical implication: the FDA prescribing information recommends discontinuing semaglutide at least two months before a planned pregnancy, because the molecule lingers in circulation long after the last dose.